Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303)

BACKGROUND: PI3K/AKT/mTOR pathway is frequently overactive in esophageal squamous cell carcinoma (ESCC), making it an attractive treatment target. BKM120 is an oral pan-class I PI3K inhibitor with promising activity in several cancers. We prospectively investigated efficacy, safety, and biomarkers o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kojima, Takashi, Kato, Ken, Hara, Hiroki, Takahashi, Shunji, Muro, Kei, Nishina, Tomohiro, Wakabayashi, Masashi, Nomura, Shogo, Sato, Akihiro, Ohtsu, Atsushi, Doi, Toshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436835/
https://www.ncbi.nlm.nih.gov/pubmed/35904643
http://dx.doi.org/10.1007/s10388-022-00928-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436835/
https://www.ncbi.nlm.nih.gov/pubmed/35904643
http://dx.doi.org/10.1007/s10388-022-00928-3

Ejemplares similares